Back to top
more

Eledon Pharmaceuticals (ELDN)

(Delayed Data from NSDQ)

$2.75 USD

2.75
44,536

-0.08 (-2.83%)

Updated Jul 17, 2024 04:00 PM ET

After-Market: $2.72 -0.03 (-1.09%) 4:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ELDN

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Eledon Pharmaceuticals, Inc. [ELDN]

Reports for Purchase

Showing records 1 - 20 ( 20 total )

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

06/04/2024

Company Report

Pages: 4

Updated Tegoprubart Results at ATC Continue to Support its First-Line Potential; Reiterate Buy and $16 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

05/10/2024

Company Report

Pages: 4

1Q24 Results and Update: Significant Tegoprubart Progress and Balance Sheet Strength

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

05/07/2024

Company Report

Pages: 4

Tegoprubart Continues to Show Safety in Organ Transplant; Reiterate Buy; Raising PT to $16

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

03/22/2024

Company Report

Pages: 4

Tegoprubart Again Impressive in Pig Kidney-to-Human Post-Transplant Maintenance

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 10.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

11/13/2023

Company Report

Pages: 4

3Q23 Results: Significant Tegoprubart Clinical Progress; Reiterate Buy Rating and $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

10/24/2023

Company Report

Pages: 5

Looking For Positive Tegorprubart Results at Kidney Week: Reiterate Buy With a New $13 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

05/26/2023

Company Report

Pages: 5

Tegoprubart Phase 1b Results in Kidney Transplant Highly Encouraging; Reiterate Buy Rating and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

01/09/2023

Daily Note

Pages: 3

Collaboration Underway For Tegoprubart in Preclinical Xenotransplantation Studies; Reiterate Buy Rating and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

11/08/2022

Daily Note

Pages: 11

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

10/18/2022

Industry Report

Pages: 9

Kidney Week - Filtering Through The Abstracts For Upcoming Meeting

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

08/16/2022

Company Report

Pages: 5

Tegoprubart Continued to Impress in 2Q22; Reiterate Buy Rating and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

08/02/2022

Daily Note

Pages: 3

FDA Clears Tegoprubart IND for Kidney Transplant Recipients; Reiterate Buy and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

07/18/2022

Daily Note

Pages: 3

First Patient Dosed in Tegoprubart Phase1b in Kidney Transplantation; Reiterate Buy and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

06/07/2022

Company Report

Pages: 5

Phase 2a Top-Line Data in ALS Met Primary Endpoints; Reiterate Buy and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

05/16/2022

Company Report

Pages: 5

Rapidly Approaching the First of Four Tegoprubart Clinical Readouts in 2022; Reiterate Buy and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

04/05/2022

Company Report

Pages: 4

Top-Line Data From Four Tegoprubart Clinical Programs Expected in 2022

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

01/14/2022

Company Report

Pages: 6

We Look to Multiple Positive AT-1501 Catalysts in 2022; Reiterate Buy and $25 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 12.50

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

11/24/2021

Company Report

Pages: 5

AT-1501 is Still Building Momentum for Multiple Catalysts in 2022; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 5.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ELDN

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Eledon Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

05/19/2021

Company Report

Pages: 6

Four Clinical Programs Set to Begin Revealing AT-1501?s Broad Therapeutic Potential; Reiterate Buy and $35 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BERNARDINO V

Price: 25.00

Research Provided by a Third Party